Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 150
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Deprecated (16384): The ArrayAccess methods will be removed in 4.0.0.Use getParam(), getData() and getQuery() instead. - /home/brlfuser/public_html/src/Controller/ArtileDetailController.php, line: 151
 You can disable deprecation warnings by setting `Error.errorLevel` to `E_ALL & ~E_USER_DEPRECATED` in your config/app.php. [CORE/src/Core/functions.php, line 311]
Warning (512): Unable to emit headers. Headers sent in file=/home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php line=853 [CORE/src/Http/ResponseEmitter.php, line 48]
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 148]
Warning (2): Cannot modify header information - headers already sent by (output started at /home/brlfuser/public_html/vendor/cakephp/cakephp/src/Error/Debugger.php:853) [CORE/src/Http/ResponseEmitter.php, line 181]
LATEST NEWS UPDATES | Major diabetes, cardiac drugs to become up to 35% cheaper -Rupali Mukherjee

Major diabetes, cardiac drugs to become up to 35% cheaper -Rupali Mukherjee

Share this article Share this article
published Published on Jul 14, 2014   modified Modified on Jul 14, 2014
-The Times of India


MUMBAI: In a move that has surprised and shaken the industry, prices of widely-used expensive anti-diabetic and cardiac medicines will reduce by as much as 35% over the next few weeks, with the drug pricing regulator, National Pharmaceutical Pricing Authority (NPPA), deciding to bring them under price control.

In a rare invocation of a lesser-used provision in the Drug Price Control Order (DPCO), NPPA has fixed the prices of 108 formulation packs of 50 anti-diabetic and cardiovascular medicines. What makes the development significant is that NPPA has fixed prices of those medicines which are not listed under the national list of essential medicines (NLEM). Prices of 652 drugs under NLEM were fixed by the government last year under DPCO 2013.

The drugs that will become cheaper include Gliclazide, Glimepiride, Sitagliptin, Voglibose, Amlodipine, Telmisartan and Rosuvastatin, Heparin and Ramipril.

The move will mean savings for patients prescribed expensive chronic therapies.

With this list, the total market of cardiac medicines under price control, including the earlier ones, stands at 58%, while 21% of the anti-diabetic market comes under the purview. Around Rs 5,500 crore of the pharma market will be impacted, with the range of prices being reduced from 10-15% to as high as 35%, with the average reduction around 12%.

The provision, Paragraph 19 of DPCO, 2013, authorizes the NPPA "in extraordinary circumstances, if it considers necessary so to do in public interest, fix the ceiling price or retail price of any drug for such period as it deems fit".

The notification to fix prices of these medicines, which are non-scheduled formulations, was issued on July 10: "...wherever the maximum retail price (MRP) of the brand of a particular formulation exceeds 25% of the simple average price, the same will be capped at the 25% level".

Simply put, if the price of a drug brand exceeds the simple average price in that therapy group by 25%, or the price at which a new drug is launched for the first time is higher than the most expensive brand existing in the group, NPPA would initiate the process of fixing a price cap.

The move which surprised many in the pharma industry, has "shaken its confidence'' and it is "examining all options''. When contacted, the industry body Indian Pharma Alliance's secretary general D G Shah said the NPPA has "gone beyond essentiality as a criterion, and into policy-making and price fixation, making the NLEM redundant".

According to the notification, NPPA has also acted on drugs where there is a "huge inter-brand price difference in branded-generics/off-patent drugs, which is indicative of a severe market failure, as different brands of the same drug formulation, including the off-patent drug, which are identical to each other in terms of active ingredient(s), strength, dosage, route of administration, quality, product characteristics, and intended use, vary disproportionately in terms of price".

"And whereas market failure alone may not constitute sufficient grounds for government intervention, but when such failure is considered in the context of the essential role that pharmaceuticals play in the area of public health, which is a social right, such intervention becomes necessary, especially when exploitative pricing makes medicines unaffordable and beyond the reach of most and also puts huge financial burden in terms of out-of-pocket expenditure on healthcare", the notification says.

The regulator says that the new law allows NPPA to fix and revise price caps of drugs in public interest and this clause applies to both drugs which are part of the NLEM and those outside of it.

Recently, NPPA, under its newly-appointed chairman Injeti Srinivas, decided to monitor prices of all drug brands in critical therapies like cancer, HIV, diabetes, cardiovascular diseases, and tuberculosis. These could be also medicines which are part of chronic treatments and exorbitantly-priced brands.

 


The Times of India, 14 July, 2014, http://timesofindia.indiatimes.com/india/Major-diabetes-cardiac-drugs-to-become-up-to-35-cheaper/articleshow/38339283.cms


Related Articles

 

Write Comments

Your email address will not be published. Required fields are marked *

*

Video Archives

Archives

share on Facebook
Twitter
RSS
Feedback
Read Later

Contact Form

Please enter security code
      Close